{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:29:49Z","timestamp":1772040589963,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"DOI":"10.7759\/cureus.22750","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T19:06:08Z","timestamp":1646161568000},"source":"Crossref","is-referenced-by-count":5,"title":["Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New Modality"],"prefix":"10.7759","author":[{"given":"Tibor","family":"Bakacs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rifaat","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3  G","family":"Pusk\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili\u00e1na Z","family":"Feh\u00e9r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imre","family":"Kovesdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and hepatitis B: current and future perspectives","volume":"12","author":"Ye J","year":"2021","unstructured":"Ye J, Chen J. Interferon and hepatitis B: current and future perspectives. Front Immunol. 2021, 12:733364. 10.3389\/fimmu.2021.733364","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill PA","year":"2019","unstructured":"Revill PA, Chisari FV, Block JM, et al.. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019, 4:545-58. 10.1016\/S2468-1253(19)30119-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90664-x","article-title":"Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor","volume":"104","author":"Ilan Y","year":"1993","unstructured":"Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology. 1993, 104:1818-1821. 10.1016\/0016-5085(93)90664-x","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane E","year":"2019","unstructured":"Gane E, Verdon DJ, Brooks AE, et al.. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol. 2019, 71:900-7. 10.1016\/j.jhep.2019.06.028","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s41124-017-0028-x","article-title":"Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs","volume":"3","author":"Bakacs T","year":"2018","unstructured":"Bakacs T, Safadi R, Kovesdi I. Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs. Hepatol Med Policy. 2018, 3:2. 10.1186\/s41124-017-0028-x","journal-title":"Hepatol Med Policy"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02751-0","article-title":"Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution","volume":"70","author":"Kleef R","year":"2021","unstructured":"Kleef R, Nagy R, Baierl A, et al.. Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution. Cancer Immunol Immunother. 2021, 70:1393-403. 10.1007\/s00262-020-02751-0","journal-title":"Cancer Immunol Immunother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202002.0147.v4","article-title":"The clinically validated viral superinfection therapy (SIT) platform technology could cure early cases of COVID-19 disease","author":"Kovesdi IS","unstructured":"Kovesdi IS, Slavin S, Renz W, Ranst MV, Chumakov PM, Bak\u00e1cs T. The clinically validated viral superinfection therapy (SIT) platform technology could cure early cases of COVID-19 disease. Preprints. 2020. 10.20944\/preprints202002.0147.v4","journal-title":"Preprints"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20303","article-title":"Healing of severe herpes zoster ophthalmicus within a few days: an autobiographical case report","volume":"13","author":"Bakacs T","year":"2021","unstructured":"Bakacs T. Healing of severe herpes zoster ophthalmicus within a few days: an autobiographical case report. Cureus. 2021, 13:e20303. 10.7759\/cureus.20303","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.09.024","article-title":"The interferon response circuit: induction and suppression by pathogenic viruses","volume":"344","author":"Haller O","year":"2006","unstructured":"Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology. 2006, 344:119-30. 10.1016\/j.virol.2005.09.024","journal-title":"Virology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.4.2630-2637.1998","article-title":"Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice","volume":"72","author":"Cavanaugh VJ","year":"1998","unstructured":"Cavanaugh VJ, Guidotti LG, Chisari FV. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol. 1998, 72:2630-7. 10.1128\/JVI.72.4.2630-2637.1998","journal-title":"J Virol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.140","article-title":"Induction of robust type I interferon levels by oncolytic reovirus requires both viral replication and interferon-\u03b1\/\u03b2 receptor signaling","volume":"32","author":"Oosenbrug T","year":"2021","unstructured":"Oosenbrug T, van den Wollenberg DJ, Duits EW, Hoeben RC, Ressing ME. Induction of robust type I interferon levels by oncolytic reovirus requires both viral replication and interferon-\u03b1\/\u03b2 receptor signaling. Hum Gene Ther. 2021, 32:1171-85. 10.1089\/hum.2021.140","journal-title":"Hum Gene Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2830","article-title":"Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies","volume":"17","author":"Horny\u00e1k \u00c1","year":"2015","unstructured":"Horny\u00e1k \u00c1, Lipinski KS, Bakonyi T, et al.. Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies. J Gene Med. 2015, 17:116-31. 10.1002\/jgm.2830","journal-title":"J Gene Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou L","year":"2001","unstructured":"Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001, 413:732-8. 10.1038\/35099560","journal-title":"Nature"},{"key":"ref14","article-title":"Adverse Effects of Interferon Treatment","author":"Aul C","year":"1997","unstructured":"Aul C, Gattermann N, Germing U, Heyll A. Adverse Effects of Interferon Treatment. Springer, Berlin Heidelberg; 1997."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2012.9","article-title":"The interferons and their receptors--distribution and regulation","volume":"90","author":"de Weerd NA","year":"2012","unstructured":"de Weerd NA, Nguyen T. The interferons and their receptors--distribution and regulation. Immunol Cell Biol. 2012, 90:483-91. 10.1038\/icb.2012.9","journal-title":"Immunol Cell Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12821","article-title":"Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer","volume":"90","author":"Bakacs T","year":"2019","unstructured":"Bakacs T, Moss RW, Kleef R, Szasz MA, Anderson CC. Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer. Scand J Immunol. 2019, 90:e12821. 10.1111\/sji.12821","journal-title":"Scand J Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.20.00084","article-title":"Real-world outcomes for patients treated with immune checkpoint inhibitors in the veterans affairs system","volume":"4","author":"La J","year":"2020","unstructured":"La J, Cheng D, Brophy MT, Do NV, Lee JS, Tuck D, Fillmore NR. Real-world outcomes for patients treated with immune checkpoint inhibitors in the veterans affairs system. JCO Clin Cancer Inform. 2020, 4:918-28. 10.1200\/CCI.20.00084","journal-title":"JCO Clin Cancer Inform"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau T","year":"2020","unstructured":"Yau T, Kang YK, Kim TY, et al.. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020, 6:e204564. 10.1001\/jamaoncol.2020.4564","journal-title":"JAMA Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13819","article-title":"FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib","volume":"26","author":"Saung MT","year":"2021","unstructured":"Saung MT, Pelosof L, Casak S, et al.. FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. Oncologist. 2021, 26:797-806. 10.1002\/onco.13819","journal-title":"Oncologist"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12913","article-title":"T-cell modulation by cyclophosphamide for tumour therapy","volume":"154","author":"Hughes E","year":"2018","unstructured":"Hughes E, Scurr M, Campbell E, Jones E, Godkin A, Gallimore A. T-cell modulation by cyclophosphamide for tumour therapy. Immunology. 2018, 154:62-8. 10.1111\/imm.12913","journal-title":"Immunology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/84550-sequential-combination-of-a-strong-interferon-inducer-viral-vector-with-low-doses-of-nivolumab-plus-ipilimumab-could-provide-functional-cure-in-chronic-hepatitis-b-virus-infections-technical-report-proposing-a-new-modality","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:13Z","timestamp":1707507613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/84550-sequential-combination-of-a-strong-interferon-inducer-viral-vector-with-low-doses-of-nivolumab-plus-ipilimumab-could-provide-functional-cure-in-chronic-hepatitis-b-virus-infections-technical-report-proposing-a-new-modality"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.22750","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}